Medics2You's is a hybrid telehealth platform that connects patients with healthcare experts around the globe with focus on Africa through a smart device from anywhere, six days a week. The company has a pilot project underway in Nigeria, a nation which spends $500m-1bn annually on outbound healthcare tourism. Medics2You aims to reach out to over 100m people unable to access quality healthcare. Medics2You's partnership with Lantum has given the company access to 18000+ doctors and 3000 clinicians. The funds will be used to create the web portal, expand the team, set up local centres, and enhance marketing activities.
days to go:
Expired
investment:
£156,370
Novai is a UK biotechnology company, developing and commercialising transformational technology in ophthalmology. The company's initial focus is on ophthalmic disorders such as glaucoma and AMD (Age-related Macular Degeneration). Novai argues that current clinical endpoints lack early disease biomarkers to objectively detect and measure cell health and response to treatment in the retina. Novai asserts that its proprietary biological marker, DARC (Detection of Apoptosis in Retinal Cells), combined with its bespoke and patented Artificial Intelligence (AI) aided algorithm, allows, for the first time in vivo, identification of cellular-level disease activity in the retina. Novai stresses that DARC can also predict disease progression, allowing for enrichment of clinical trial cohorts. The company anticipates an exit via licensing of its biomarker business to a Contract Research Organisation (CRO), an Initial Public Offering (IPO) following a successful phase 3 trial of the diagnostic platform, or trade sale to a strategic pharmaceutical company.
days to go:
Expired
investment:
£1,314,967
Hypha is an innovation intelligence platform. The company combines ontology mapping and graph processing to connect and leverage knowledge such that it is contextually aligned to an enterprise’s unique structure, systems, processes, and strategic objectives. Hypha deploys features on its platform such as clustering boards, browser extension tools, custom branding, and cloud-based deployment to help organisations achieve growth and profitability. The company has onboarded multiple entities on its integration roadmap, such as Miro, Microsoft Teams, Office 365, GSuite, and Dropbox, to name a few. The company has secured 6 enterprise clients worldwide, with IKEA as one of their illustrious clients. It will use 80% of the investment for product development and 20% for sales and marketing.
days to go:
Expired
investment:
£222,100
Kalendit removes the middleman (agencies) and provides UK nurseries with temporary staff while helping them save up to 50% on staffing fees. Since September, over 150 users joined Kalendit, and it is continuing to add about two workers daily. This company had launched its services in November with four nurseries, and since then, have been successfully processed 49 bookings. With the funds raised, it will hire people and serve thirty nurseries in one year. By the fifth year, it wants to take 45% of the London market, which equates to 1400 nurseries.
days to go:
Expired
investment:
£82,180
MyT is a cloud-powered subscription-based accounting software designed for small businesses that allows them to submit financial information to Her Majesty's Revenue and Customs (HMRC) under the Making Tax Digital initiative, which is mandatory from April 2023. MyT asserts that its app provides businesses with a simple way to keep track of business finances on the go, send and manage invoices and bills, and record expenses and mileage. The company claims that its app is available on App Store and Google Play and has witnessed 1000+ downloads to date. It claims that it has onboarded over 500 users without any extensive marketing spend. MyT will use half of the investment to implement its marketing plan, a third for developing new technology and the remaining for administrative expenses.
days to go:
Expired
investment:
£133,543
Lessgo is a real-life social networking platform that allows users to have shared experiences with like-minded people in small and comfortable groups. The app allows users to engage in the pursuit of similar interests like a bike ride, a park run, have a drink, share moments after work, or have a meet-up. The company has acquired 800+ registered users through invite-only sign-up since its release in April 2021. It launched its successful beta between September–November 2020 with hundreds of organic users based around London and has witnessed 1500+ installs in the UK to date on iOS and Android. It will use the investment for growth marketing programmes, expand its team, and operations management.
days to go:
Expired
investment:
£122,070
Gartenzwerg is a fully automated and beautifully designed indoor gardening system with which you can have small fruits, vegetables and herbs year-round right from home.
days to go:
Expired
investment:
£117,352
Cuckoo is an internet broadband provider. The company claims that incumbent internet providers treat customers with poor customer service, high prices, and complicated contracts. Cuckoo aims to change this by providing users with fair and transparent prices, simple contracts, high-quality routers, and responsive customer service. The company is currently developing its website and billing engine ahead of launching with its first customers in the second quarter of 2020. Cuckoo's business is in the pre-revenue stage. It expects to start generating revenue in May/June 2020 when they launch their broadband service. Cuckoo will use 50% of the investment towards paying salaries to staff, 25% as technology development fees, 10% as professional fees, 5% as rent, and 10% as AOB. Cuckoo's exit strategy is via a trade sale or listing in the United Kingdom.
days to go:
Expired
investment:
£69,622
The Booking Factory is designed to create and maintain hotel websites so you don't have to worry about it needing updates or security fixes. The Booking Factory will create you a hotel website that will allow you to easily manage your bookings, automate your admin and engage more with your guests.
days to go:
Expired
investment:
£33,560
Inspira Pharmaceuticals (IP) is forming a possible new therapy for COVID-19. IP asserts that its in-lab plant-based molecular formulation has killed over 95% of the SARS-CoV-2 virus. The company aims to understand whether a COVID-19 patient can safely inhale the formulation directly into their lungs as an effective treatment. IP has secured cornerstone investment from biotech angel investors and a Singaporean Venture Capitalist (VC) for its formula. IP argues that its technology has the potential for addressing other respiratory infections such as cystic fibrosis, influenza and the common cold in the coming months. The company will use the investment to develop an effective new drug, which will include further laboratory analysis, safety testing, and preparation for human trials.
days to go:
Expired
investment:
£357,179
